GLOBAL-BLUE
21.4.2021 12:33:09 CEST | Business Wire | Press release
Global Blue, today, announced the launch of Global Blue Ventures, a new entity created to identify, invest in and/or partner with third parties that offer market-leading retail technology solutions.
Global Blue Ventures was initiated in 2019, and officially launched in April 2021, to advance Global Blue’s ambition to be a strategic omnichannel technology and payments partner empowering merchants to improve their performance.
Extending Global Blue’s value proposal with innovative omnichannel solutions
Global Blue Ventures concentrates on innovative and promising new businesses, with best-in-class companies selected to support brands on their omnichannel path.
The Ventures program will focus on add-on technologies that can easily integrate with retailers’ core systems, allowing them to:
- Optimise and digitalise their processes across the entire omnichannel customer journey: online, in store and at home
- Capture customers’ identity and engage with them on a personalised one-to-one basis
- Collect and cross-reference data to provide advisory services and actionable insights
It will focus its efforts on three key verticals and market needs:
- eCommerce: how to boost conversion rates and improve return efficiency
- Store digitalisation: how to digitalise in-store processes and experiences
- Clienteling 2.0: how to engage digitally one-to-one with consumers
RetailTech market experts James Strabo, previously a founding member and Managing Director at Blackhawk Network and Managing Director at Westfield (OneMarket), and Andrew Carroll, Founder of Yocuda and formerly Director of Corporate Development at Westfield (OneMarket) will lead Global Blue Ventures. Their mission will be to pinpoint latest retail market trends, identify the best-in-class technology players for each vertical, test and collect retailers’ feedback and, where appropriate, drive investments in the retail technology partners that can further accelerate Global Blue’s omnichannel market expansion.
Advancing with investment in promising new verticals
Since its inception, Global Blue Ventures has already enabled Global Blue to join forces with several leading players including:
- Yocuda: in October 2020, Global Blue acquired a minority stake in Yocuda, a leading digital receipt provider. Yocuda allows retailers to send content-rich, personalised digital receipts to consumers, whilst capturing data that allows for customer insight, management and engagement. Its technology can also be linked to a brand loyalty programmes. Yocuda is partnered with leading companies such as Marks & Spencer and Argos.
- ZigZag Global: in March 2021, Global Blue announced the acquisition of ZigZag Global, a leading Software-as-a-Service (SaaS) technology provider. ZigZag replaces the traditional paper-based “label in the box” returns solution with an online portal that enhances the experience for consumers and streamlines the process for retailers across the world. ZigZag is partnered with leading retailers such as Selfridges and Superdry.
Jacques Stern, CEO of Global Blue: “As a technology and payment partner for retailers, we are looking at extending our solutions on the full omnichannel journey, for both domestic and international shoppers. The network of RetailTech companies that we have started to create through Global Blue Ventures will enable us to co-create integrated solutions that achieve this goal and ensure we continue to meet our clients’ evolving needs.”
James Strabo and Andrew Carroll, Founding Partners of Global Blue Ventures: “ We are very pleased to be joining Global Blue and look forward to bringing our vision and expertise to help propel the business further into the RetailTech space. We are confident that the network of RetailTech partners we will build will give Global Blue clients access to the best-in-class solutions and will enable them to stay at the forefront of the latest omnichannel trends.”
ABOUT GLOBAL BLUE
Global Blue is a long-standing and trusted partner for retailers across the world. Its omnichannel technology and payments solutions empower its clients to improve their performance in the following areas:
- Tax Free Shopping: After pioneering the concept of Tax-Free Shopping more than 40 years ago, Global Blue’s integrated technology solutions at 300,000 points of sale offer 13 million international shoppers a seamless and personalised experience when claiming back the VAT on goods purchased abroad.
- Added Value Payment Solutions: Global Blue partners with more than 50 acquirers and Payment Service Providers across the world to provide retailers and hoteliers with a best-in-class FX solution that serves 16 million travellers and online shoppers at more than 130,000 points of interaction.
- Ecommerce returns: Global Blue offers, through its ZigZag Global brand, an enhanced, fully digital returns experience to more than 12 million domestic shoppers by connecting retailers to a network of more than 450 carrier services and 220 warehouses in 130 countries.
A unique understanding of shoppers and their shopping history enables Global Blue to provide Advisory Business Intelligence services, helping retailers to identify revenue and costs opportunities, while its Consumer Engagement solutions help retailers to capture growth opportunities.
In the financial year ending 31 March 2020, Global Blue processed 35 million Tax Free Shopping transactions with a total value of €18.5 billion sales in store, and 31 million Added-Value Payment Solutions transactions with a total value of €4.4 billion sales in store. Global Blue has almost 1,500 employees and is present in more than 50 countries.
Global Blue is listed on the New York Stock Exchange under the ticker GB.
For more information : globalblue.com/corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005512/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
